The Promise of CGRP Targeted Therapies in the Treatment and
Prevention of Migraines: What Managed Care Needs to Know in
the Evolving Treatment Paradigm


 

A continuing medical education activity sponsored by NAMCP and AAMCN 

The Promise of CGRP Targeted Therapies in the Treatment and Prevention of Migraines: What Managed
Care Needs to Know in the Evolving Treatment Paradigm is a 3-part webcast series that will provide
attendees with the latest information in the management of migraines.

 By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

These are archives of live webinars held between June 14, 2019 and June 27, 2019.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

 Each session has its own specific valid dates

This series is supported by an educational grant from Teva Pharmaceuticals

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

 Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Migraine is a major neurological disease that affects more than 36 million men, women and children in the US. Migraine headache is the most common type of headache presented by patients that seek medical treatment, and the WHO has ranked migraine in the top fifteen most disabling medical conditions. Although approximately 38% of migraineurs need preventive therapy, only 3% to 13% currently use it. Fortunately for patients who suffer from migraine headaches, a new class of therapy is emerging that has shown to offer vastly improved efficacy and safety over traditional treatment regimens. Three calcitonin gene-related peptide (CGRP) monoclonal antibodies have recently been approved that offer healthcare professionals a new and improved armamentarium in the treatment and prevention of migraines. 


Migraines: Strategies for Anticipating and Managing Adverse Events in Anti-CGRP Therapies 

  1. Explore challenges to patient adherence and quality of life in migraines
  2. Discuss the importance of patient education, trigger avoidance, and treatment adherence strategies when addressing migraines
  3. Analyze strategies to monitor and manage adverse events associated with anti-CGRP therapies in migraine management in order to improve patient adherence
  4. Review recent clinical data around the safety of anti-CGRP therapies and their effect on patient quality of life
       Physician, Nursing and CMCN credits valid to August 1, 2020

A Deeper Look into Anti-CGRP Therapies in the Treatment and Prevention of Migraines: Improving Clinical and Economic Outcomes 

  1. Identify the unmet clinical needs resulting from ineffective preventive treatments in migraines
  2. Analyze the role of calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine
  3. Compare and contrast the efficacy and safety of recently approved and emerging anti-CGRP treatments in the preventive treatment of migraines
  4. Identify patients with episodic or chronic migraine who might benefit from preventive treatment with anti-CGRP monoclonal antibodies
       Physician, Nursing and CMCN credits valid to August 1, 2020

Comparative Effectiveness and Coordinated Care in Migraines: What Does Managed Care Need to Know about Anti-CGRP Therapies?

  1. Examine the impact migraine has on pharmacoeconomics and total cost of patient care
  2. Assess the managed care considerations of anti-CGRP therapies by exploring where the implementation of these agents into the evolving migraine treatment paradigm
  3. Discuss methods to enable optimal cost management of anti-CGRP therapies to be realized by multiple migraine stakeholders including managed care organizations
  4. Explore interventions to coordinate health plan and affiliated provider's efforts that will lead to better outcomes for patients with migraines
       Physician, Nursing and CMCN credits valid to August 1, 2020